Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Characteristics of patients under study

From: Androgen conversion in osteoarthritis and rheumatoid arthritis synoviocytes – androstenedione and testosterone inhibit estrogen formation and favor production of more potent 5α-reduced androgens

  Osteoarthritis Rheumatoid arthritis
n 26 25
Age, years 71 ± 2 [55–88] 66 ± 2 [39–84]
Gender, F/M 21/5 (81/19) 19/6 (76/24)
Disease duration, years§ 5 ± 1 10 ± 1
Erythrocyte sedimentation rate, mm/1st hr 16.6 ± 3.2 35.2 ± 7.2**
C-reactive protein, mg/l 6.6 ± 0.9 26.3 ± 7.5#
Rheumatoid factor positive 1/26 (0.5) 12/25 (48.0)
Lining layer, cells 2.1 ± 0.1 3.9 ± 0.3##
Cell density, cells/mm2 1257 ± 121 1864 ± 202**
T cell density, cells/mm2 22.2 ± 4.7 58.8 ± 20.1
CD163+ macrophage density, cells/mm2 54.7 ± 10.1 101.3 ± 20.5*
Vascularity, vessels/mm2 28.8 ± 2.9 31.1 ± 3.7
Medication   
   Prednisolone n.a. 19 (76.0)
   Mean prednisolone dose, mg/d n.a. 5.2 ± 0.9
   NSAIDs 14/26 (54.0) 20/25 (80.0)
   Methotrexate n.a. 4/25 (16.0)
   Leflunomide n.a. 8/25 (32.0)
   Azathioprine n.a. 1/25 (4.0)
   Sulfasalazine n.a. 1/25 (4.0)
   Hydroxychloroquine n.a. 4/25 (16.0)
   Cyclosporin A n.a. 1/25 (4.0)
   Anti-TNF therapy strategies n.a. 0/25 (0.0)
  1. *p = 0.065, **p < 0.05, #p < 0.01, ##p < 0.001 for the comparison versus osteoarthritic patients. §Disease duration in OA patients is a rough estimate because the exact starting point is often not precisely known. Data are given as means ± SEM, percentages in parentheses, and ranges in square brackets. F/M, female/male; n.a., not applicable; NSAIDs, non-steroidal anti-inflammatory drugs; TNF, tumor necrosis factor.